A Single-center, Prospective, Two Cohort Study of Surufatinib Combined With AG or AG in the First-line Treatment of Locally Advanced or Metastatic Pancreatic Cancer

This study is testing whether adding a targeted drug called surufatinib to a standard chemotherapy regimen (gemcitabine plus nab-paclitaxel) improves outcomes for people with locally advanced or metastatic pancreatic cancer. Surufatinib blocks blood vessel growth in tumors and also has immune-boosting properties. This is a first-line maintenance approach for patients who have already started standard chemotherapy and their disease has not progressed. **You may be eligible if...** - You have confirmed locally advanced or metastatic pancreatic cancer (not surgically removable) - You are between 18 and 75 years old - You have already received 2 cycles of gemcitabine + nab-paclitaxel (AG regimen) with stable or responding disease - Your general health is good (ECOG 0–1) with a life expectancy of at least 12 weeks - Your blood counts, liver, and kidney function are within acceptable ranges **You may NOT be eligible if...** - Your cancer progressed during the initial 2 cycles of chemotherapy - You have serious heart, lung, or brain organ disease - You have received prior chemotherapy for metastatic pancreatic cancer (other than the 2 AG cycles described above) within 6 months - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.